Clinical trial
PK Effects of Bifeprunox & Valproate in Bipolar I
NCT00141505 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00141505 |
|---|---|
| Title | PK Effects of Bifeprunox & Valproate in Bipolar I |
| Official title | Placebo-controlled Study on the Pharmacokinetics,Pharmacodynamics, Safety and Tolerability of Concurrent Valproate and Bifeprunox Administration in Subjects With Bipolar I Disorder |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Collaborators | H. Lundbeck A/S Industry Wyeth is now a wholly owned subsidiary of Pfizer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bipolar I Disorder |
| Intervention type | Drug |
| Interventions | Bifeprunox |
| Start date | Feb 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Jan 16, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: